neogenomics inc. - NEO
NEO
Close Chg Chg %
17.56 0.22 1.22%
Open Market
17.78
+0.22 (1.22%)
Volume: 671.12K
Last Updated:
Sep 9, 2026, 3:10 PM EDT
Company Overview: neogenomics inc. - NEO
NEO Key Data
| Open $17.28 | Day Range 17.15 - 17.99 |
| 52 Week Range 7.07 - 19.76 | Market Cap $2.23B |
| Shares Outstanding 128.48M | Public Float 126.01M |
| Beta 1.75 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$0.40 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 1.70M |
NEO Performance
| 1 Week | 1.04% | ||
| 1 Month | 5.97% | ||
| 3 Months | 57.49% | ||
| 1 Year | 120.60% | ||
| 5 Years | -66.57% |
NEO Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
12
Full Ratings ➔
About neogenomics inc. - NEO
NeoGenomics, Inc. is a clinical laboratory company, which engages in cancer genetics diagnostic testing and pharma services. The company was founded by Michael T. Dent on October 29, 1998 and is headquartered in Fort Myers, FL.
NEO At a Glance
NeoGenomics, Inc.
9490 NeoGenomics Way
Fort Myers, Florida 33912
| Phone | 1-239-768-0600 | Revenue | 727.33M | |
| Industry | Medical/Nursing Services | Net Income | -108,025,000.00 | |
| Sector | Health Services | 2025 Sales Growth | 10.107% | |
| Fiscal Year-end | 12 / 2026 | Employees | 2,500 | |
| View SEC Filings |
NEO Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 2.071 |
| Price to Book Ratio | 1.813 |
| Price to Cash Flow Ratio | 288.04 |
| Enterprise Value to EBITDA | 1,006.479 |
| Enterprise Value to Sales | 2.415 |
| Total Debt to Enterprise Value | 0.233 |
NEO Efficiency
| Revenue/Employee | 290,932.80 |
| Income Per Employee | -43,210.00 |
| Receivables Turnover | 4.553 |
| Total Asset Turnover | 0.485 |
NEO Liquidity
| Current Ratio | 4.26 |
| Quick Ratio | 3.936 |
| Cash Ratio | 1.808 |
NEO Profitability
| Gross Margin | 38.846 |
| Operating Margin | -9.085 |
| Pretax Margin | -15.161 |
| Net Margin | -14.852 |
| Return on Assets | -7.207 |
| Return on Equity | -12.425 |
| Return on Total Capital | -8.67 |
| Return on Invested Capital | -8.49 |
NEO Capital Structure
| Total Debt to Total Equity | 48.945 |
| Total Debt to Total Capital | 32.861 |
| Total Debt to Total Assets | 30.111 |
| Long-Term Debt to Equity | 48.374 |
| Long-Term Debt to Total Capital | 32.478 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Neogenomics Inc. - NEO
Collapse All in section
| All values USD millions. | 2022 | 2023 | 2024 | 2025 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 509.73M | 591.64M | 660.57M | 727.33M | |
Sales Growth
| +5.24% | +16.07% | +11.65% | +10.11% | |
Cost of Goods Sold (COGS) incl D&A
| 336.48M | 382.17M | 403.91M | 444.79M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 79.20M | 72.58M | 72.55M | 67.82M | |
Depreciation
| 45.15M | 37.45M | 39.10M | 36.07M | |
Amortization of Intangibles
| 34.06M | 35.13M | 33.45M | 31.75M | |
COGS Growth
| +10.41% | +13.58% | +5.69% | +10.12% | |
Gross Income
| 173.25M | 209.47M | 256.65M | 282.54M | |
Gross Income Growth
| -3.52% | +20.91% | +22.52% | +10.09% | |
Gross Profit Margin
| +33.99% | +35.40% | +38.85% | +38.85% |
| 2022 | 2023 | 2024 | 2025 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 323.88M | 306.12M | 328.35M | 348.62M | |
Research & Development
| 30.33M | 27.31M | 31.16M | 37.08M | |
Other SG&A
| 293.55M | 278.81M | 297.19M | 311.54M | |
SGA Growth
| +17.87% | -5.48% | +7.26% | +6.17% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| 7.00M | 11.09M | 20.41M | 49.80M | |
EBIT after Unusual Expense
| (157.62M) | (107.74M) | (92.11M) | (115.88M) | |
Non Operating Income/Expense
| (213.00K) | 17.55M | 18.05M | 9.37M | |
Non-Operating Interest Income
| - | 16.90M | 18.43M | 9.07M | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| 1.51M | 6.91M | 6.62M | 3.75M | |
Interest Expense Growth
| -70.37% | +358.63% | -4.20% | -43.28% | |
Gross Interest Expense
| 1.51M | 6.91M | 6.62M | 3.75M | |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (159.34M) | (97.10M) | (80.67M) | (110.27M) | |
Pretax Income Growth
| -957.00% | +39.06% | +16.91% | -36.68% | |
Pretax Margin
| -31.26% | -16.41% | -12.21% | -15.16% | |
Income Tax
| (15.09M) | (9.13M) | (1.95M) | (2.24M) | |
Income Tax - Current - Domestic
| 135.00K | 391.00K | 546.00K | 866.00K | |
Income Tax - Current - Foreign
| - | - | 17.00K | 79.00K | - |
Income Tax - Deferred - Domestic
| (33.00K) | 229.00K | (331.00K) | 277.00K | |
Income Tax - Deferred - Foreign
| (15.21M) | (9.75M) | (2.24M) | (3.39M) | |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (144.25M) | (87.97M) | (78.73M) | (108.03M) | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| (144.25M) | (87.97M) | (78.73M) | (108.03M) | |
Net Income Growth
| -1,628.17% | +39.02% | +10.51% | -37.22% | |
Net Margin Growth
| -28.30% | -14.87% | -11.92% | -14.85% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (144.25M) | (87.97M) | (78.73M) | (108.03M) | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (144.25M) | (87.97M) | (78.73M) | (108.03M) | |
EPS (Basic)
| -1.1613 | -0.7009 | -0.6216 | -0.8433 | |
EPS (Basic) Growth
| -1,568.53% | +39.65% | +11.31% | -35.67% | |
Basic Shares Outstanding
| 124.22M | 125.50M | 126.66M | 128.10M | |
EPS (Diluted)
| -1.1613 | -0.7009 | -0.6216 | -0.8433 | |
EPS (Diluted) Growth
| -1,568.53% | +39.65% | +11.31% | -35.67% | |
Diluted Shares Outstanding
| 124.22M | 125.50M | 126.66M | 128.10M | |
EBITDA
| (71.42M) | (24.07M) | 852.00K | 1.75M | |
EBITDA Growth
| -115.51% | +66.31% | +103.54% | +104.81% | |
EBITDA Margin
| -14.01% | -4.07% | +0.13% | +0.24% |
Snapshot
| Average Recommendation | OVERWEIGHT | Average Target Price | 16.778 | |
| Number of Ratings | 12 | Current Quarters Estimate | 0.054 | |
| FY Report Date | 09 / 2026 | Current Year's Estimate | 0.183 | |
| Last Quarter’s Earnings | 0.05 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | 0.12 | Next Fiscal Year Estimate | 0.338 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 11 | 11 | 11 | 11 |
| Mean Estimate | 0.05 | 0.07 | 0.18 | 0.34 |
| High Estimates | 0.07 | 0.08 | 0.20 | 0.41 |
| Low Estimate | 0.04 | 0.06 | 0.16 | 0.28 |
| Coefficient of Variance | 20.88 | 12.03 | 7.38 | 11.36 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 8 | 8 | 8 |
| OVERWEIGHT | 0 | 0 | 0 |
| HOLD | 4 | 4 | 4 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Overweight | Overweight | Overweight |
SEC Filings for Neogenomics Inc. - NEO
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Neogenomics Inc. - NEO
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Jan 16, 2026 | Alicia C. Olivo EVP, GC & Business Development | 90,465 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jan 16, 2026 | Alicia C. Olivo EVP, GC & Business Development | 75,320 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 | 0.00 |
| Jan 16, 2026 | Warren Stone Pres & Chief Operating Officer | 158,886 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jan 16, 2026 | Warren Stone Pres & Chief Operating Officer | 143,759 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 | 0.00 |
| Jan 7, 2026 | John Patrick Kenny Director | 4,171 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jan 7, 2026 | John Patrick Kenny Director | 5,893 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |